New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
出版年份 2022 全文链接
标题
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
作者
关键词
-
出版物
DRUG RESISTANCE UPDATES
Volume 64, Issue -, Pages 100849
出版商
Elsevier BV
发表日期
2022-07-01
DOI
10.1016/j.drup.2022.100849
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC
- (2022) Kevin Zhou et al. Molecular Cancer
- Endothelial p130cas confers resistance to anti-angiogenesis therapy
- (2022) Yunfei Wen et al. Cell Reports
- Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors
- (2022) Yingzhuo Xu et al. Cell Death Discovery
- Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma
- (2022) Yu-Yun Shao et al. BRITISH JOURNAL OF CANCER
- Transcriptional suppression of Dicer by HOXB‐AS3/EZH2 complex dictates sorafenib resistance and cancer stemness
- (2022) Chi‐Feng Tseng et al. CANCER SCIENCE
- The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells
- (2022) Cristina P.R. Xavier et al. DRUG RESISTANCE UPDATES
- Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma
- (2022) Manfei Pi et al. DRUG RESISTANCE UPDATES
- Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma
- (2022) Danyang Li et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance
- (2021) Wei Zhao et al. BRITISH JOURNAL OF CANCER
- A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway
- (2021) Wei Xie et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments
- (2021) Xiaoxu Wei et al. Molecular Cancer
- Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling
- (2021) Kuo-Hao Ho et al. Neurotherapeutics
- Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target
- (2021) Lucas Treps et al. PHARMACOLOGY & THERAPEUTICS
- Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
- (2021) Andrew J. Brenner et al. Scientific Reports
- HSP90α Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia
- (2021) Yan Liao et al. Cancers
- HDAC11 regulates glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness
- (2021) Lei Bi et al. CANCER RESEARCH
- Emerging Role of Autophagy in Anti-Tumor Immunity: Implications for the Modulation of Immunotherapy Resistance
- (2021) Ting Jiang et al. DRUG RESISTANCE UPDATES
- CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
- (2021) Masahiro Nishikawa et al. Cancer Medicine
- Quiescin Sulfhydryl Oxidase 1 Promotes Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving EGFR Endosomal Trafficking and Inhibiting NRF2 Activation
- (2021) Jialei Sun et al. Redox Biology
- EPHB2 activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma
- (2021) Hoi-Wing Leung et al. CANCER RESEARCH
- Cyr61 from adipose‐derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin α V β 5
- (2021) Zhenxing Liang et al. Molecular Oncology
- Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
- (2021) Zowi R. Huinen et al. Nature Reviews Clinical Oncology
- Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma
- (2021) Shuhei Kamada et al. ONCOGENE
- GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis
- (2021) Qiujie Wang et al. Cell Death & Disease
- TNFα secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy
- (2021) Qingxia Wei et al. Acta Neuropathologica Communications
- Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy
- (2021) Damien Ambrosetti et al. BJU INTERNATIONAL
- Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling
- (2021) Miao He et al. CANCER LETTERS
- FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness
- (2021) Jia Jian Loh et al. CANCER RESEARCH
- The BAFF/NFκB axis is crucial to interactions between sorafenib‐resistant HCC cells and cancer‐associated fibroblasts
- (2021) Luping Gao et al. CANCER SCIENCE
- Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
- (2021) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- A multi-locus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer
- (2021) GuoXiang Cai et al. GASTROENTEROLOGY
- Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights
- (2021) Asumi Iesato et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC
- (2021) Sonia A. Patel et al. Journal of Thoracic Oncology
- Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
- (2021) Peter R Galle et al. LANCET ONCOLOGY
- Clinical and therapeutic relevance of cancer-associated fibroblasts
- (2021) Yang Chen et al. Nature Reviews Clinical Oncology
- CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance
- (2021) Shaolin Ma et al. Cell Reports
- Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer
- (2021) Joaquim Bosch-Barrera et al. Cancers
- Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma
- (2021) Zichan Dai et al. CANCER LETTERS
- Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway
- (2021) Maohua Huang et al. CANCER LETTERS
- A Combinatorial CRISPR–Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment
- (2021) Feng Xu et al. CANCER RESEARCH
- Hypoxia as a driver of resistance to immunotherapy
- (2021) Joanna Kopecka et al. DRUG RESISTANCE UPDATES
- Impact of cancer metabolism on therapy resistance – Clinical implications
- (2021) Ana Cristina Gonçalves et al. DRUG RESISTANCE UPDATES
- YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis
- (2021) Ruize Gao et al. EMBO Molecular Medicine
- Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
- (2021) Zelalem Temesgen et al. Lancet Respiratory Medicine
- Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis
- (2021) Xueying Ren et al. Redox Biology
- New Insights Into the Regulatory Roles of Extracellular Vesicles in Tumor Angiogenesis and Their Clinical Implications
- (2021) Maohua Huang et al. Frontiers in Cell and Developmental Biology
- circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma
- (2021) Pengfei Zhang et al. Molecular Therapy-Nucleic Acids
- Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer
- (2020) J. Moss et al. ANNALS OF ONCOLOGY
- Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
- (2020) Naoki Horikawa et al. BRITISH JOURNAL OF CANCER
- Clonal ZEB1-driven mesenchymal transition promotes targetable oncologic anti-angiogenic therapy resistance
- (2020) Ankush Chandra et al. CANCER RESEARCH
- MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma
- (2020) Laura Gramantieri et al. CANCER RESEARCH
- Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
- (2020) Kenji Ichikawa et al. Scientific Reports
- Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
- (2020) Qing Zhou et al. Genome Medicine
- miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance
- (2020) Tao Han et al. Molecular Therapy-Nucleic Acids
- ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation
- (2020) Qinghai Lin et al. EBioMedicine
- Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
- (2020) Makoto Chuma et al. Cancers
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
- (2020) Marjut Niinivirta et al. BMC CANCER
- NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma
- (2020) Hoi Wing Leung et al. CANCER LETTERS
- RNA m 6 A methylation regulates sorafenib resistance in liver cancer through FOXO 3‐mediated autophagy
- (2020) Ziyou Lin et al. EMBO JOURNAL
- Vasculogenic mimicry in carcinogenesis and clinical applications
- (2020) Qingxi Luo et al. Journal of Hematology & Oncology
- Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma
- (2020) Lei Fan et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC
- (2020) Junfei Gu et al. Cell Death & Disease
- Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma
- (2020) Tatjana Seitz et al. Scientific Reports
- SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR‐23b‐3p via sponging EGR1 in hepatocellular carcinoma
- (2020) Zhao Jing et al. Cancer Medicine
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
- (2020) Zhong-jie Li et al. ACTA PHARMACOLOGICA SINICA
- Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
- (2020) Giovanna Li Petri et al. BRITISH JOURNAL OF CANCER
- Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer
- (2020) Ying Shen et al. CANCER CELL
- Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis
- (2020) Stefano Indraccolo et al. CLINICAL CANCER RESEARCH
- Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial
- (2020) Giuseppe Pasqualetti et al. EUROPEAN JOURNAL OF CANCER
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Patients Receiving Regorafenib
- (2020) Yingmiao Liu et al. MOLECULAR CANCER THERAPEUTICS
- Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth
- (2020) Tanguy Lechertier et al. Nature Communications
- A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
- (2020) Matthias Unseld et al. INTERNATIONAL JOURNAL OF CANCER
- PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer
- (2020) Lucrezia Raimondi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth
- (2020) Abul K. Azad et al. ONCOGENE
- Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer
- (2020) Yoshiro Itatani et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer
- (2020) Haoran Feng et al. Cell Death & Disease
- The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma
- (2020) Zhongqiang Zhang et al. Cell Death & Disease
- Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo
- (2020) Xiaoxia Liu et al. Redox Biology
- Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance
- (2020) Jiaye Liu et al. Cellular and Molecular Gastroenterology and Hepatology
- ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma
- (2020) Yuta Myojin et al. CLINICAL CANCER RESEARCH
- Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
- (2020) Nuray Erin et al. DRUG RESISTANCE UPDATES
- Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
- (2020) Thi Bich Uyen Le et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis
- (2020) Hong Wu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Vessel co-option in cancer
- (2019) Elizabeth A. Kuczynski et al. Nature Reviews Clinical Oncology
- Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition
- (2019) Anthony S. Fischl et al. MOLECULAR CANCER THERAPEUTICS
- Monocyte heterogeneity and functions in cancer
- (2019) Claire E. Olingy et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
- (2019) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma
- (2019) Ningning Dong et al. BRITISH JOURNAL OF CANCER
- Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance
- (2019) Dai-Min Xiang et al. GUT
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Exosomes and their role in tumorigenesis and anticancer drug resistance
- (2019) Neta Milman et al. DRUG RESISTANCE UPDATES
- Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
- (2019) Iris Uribesalgo et al. EMBO Molecular Medicine
- Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A
- (2019) Elke Burgermeister et al. EBioMedicine
- HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib
- (2019) Zhen Song et al. CANCER LETTERS
- The multi-factorial nature of clinical multidrug resistance in cancer
- (2019) Yehuda G. Assaraf et al. DRUG RESISTANCE UPDATES
- Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression
- (2019) Hangchuan Shi et al. ONCOGENE
- Autophagy as a mechanism for anti-angiogenic therapy resistance
- (2019) Ankush Chandra et al. SEMINARS IN CANCER BIOLOGY
- SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity
- (2019) Fan Yin et al. Cell Death & Disease
- Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial
- (2019) Eric Van Cutsem et al. CLINICAL CANCER RESEARCH
- Pexidartinib: First Approval
- (2019) Yvette N. Lamb DRUGS
- USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation
- (2019) Sunbin Ling et al. GUT
- miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy
- (2019) Wen-Ping Xu et al. GUT
- Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
- (2019) Lai Wei et al. Nature Communications
- Vessel co-option and resistance to anti-angiogenic therapy
- (2019) Elizabeth A. Kuczynski et al. ANGIOGENESIS
- Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
- (2019) Joanna Kopecka et al. DRUG RESISTANCE UPDATES
- Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
- (2019) Silpa Narayanan et al. DRUG RESISTANCE UPDATES
- Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance
- (2019) M. Helena Vasconcelos et al. DRUG RESISTANCE UPDATES
- Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy
- (2019) Matteo Curtarello et al. Cells
- The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma
- (2018) Helena Polena et al. BRITISH JOURNAL OF CANCER
- A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment
- (2018) Amelie Griveau et al. CANCER CELL
- Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy
- (2018) Raimund Bauer et al. CANCER RESEARCH
- IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
- (2018) Bowie Y. Cheng et al. CANCER RESEARCH
- Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway
- (2018) Regina Cheuk-Lam Lo et al. CELL DEATH AND DIFFERENTIATION
- Obesity Protects Cancer from Drugs Targeting Blood Vessels
- (2018) Yihai Cao Cell Metabolism
- Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
- (2018) Hideki Iwamoto et al. Cell Metabolism
- How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
- (2018) Philippe Icard et al. DRUG RESISTANCE UPDATES
- Redundant angiogenic signaling and tumor drug resistance
- (2018) Rajesh N. Gacche et al. DRUG RESISTANCE UPDATES
- Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients
- (2018) Paola Romeo et al. ENDOCRINE-RELATED CANCER
- Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib
- (2018) Man Tong et al. JOURNAL OF HEPATOLOGY
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study
- (2018) Andrew Brenner et al. NEURO-ONCOLOGY
- VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
- (2018) Signe R Michaelsen et al. NEURO-ONCOLOGY
- Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
- (2018) Joao Incio et al. Science Translational Medicine
- Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
- (2018) Jie Zhou et al. SEMINARS IN IMMUNOLOGY
- PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib
- (2018) Kai Zhang et al. Cell Death & Disease
- CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
- (2018) Shuai Lu et al. Cell Death & Disease
- Periostin Limits Tumor Response to VEGFA Inhibition
- (2018) Ioanna Keklikoglou et al. Cell Reports
- HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport
- (2018) Peihua Luo et al. Autophagy
- FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA
- (2018) Shuyang Wang et al. CANCER LETTERS
- Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth
- (2018) Victor LJL Thijssen et al. JOURNAL OF PATHOLOGY
- Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma
- (2018) Thomas Simon et al. Molecular Cancer
- Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer
- (2018) Weiwei Yu et al. ONCOGENE
- VEGF-B is a potent antioxidant
- (2018) Pachiappan Arjunan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
- (2018) Tianrun Liu et al. Nature Communications
- Autophagy Inhibition Promotes Bevacizumab-induced Apoptosis and Proliferation Inhibition in Colorectal Cancer Cells
- (2018) Zhi Zhao et al. Journal of Cancer
- CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy–Resistant Glioblastoma
- (2018) Kartik Angara et al. NEOPLASIA
- Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
- (2018) Lars Mortimer Schiffmann et al. BRITISH JOURNAL OF CANCER
- Glioblastoma endothelium drives bevacizumab‐induced infiltrative growth via modulation of PLXDC1
- (2018) Maria Laura Falchetti et al. INTERNATIONAL JOURNAL OF CANCER
- Genetic variants in CCL5 and CCR5 genes and serum VEGF‐A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients
- (2018) Mitsukuni Suenaga et al. INTERNATIONAL JOURNAL OF CANCER
- Turning foes to friends: targeting cancer-associated fibroblasts
- (2018) Xueman Chen et al. NATURE REVIEWS DRUG DISCOVERY
- Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity
- (2018) Benny Zhitomirsky et al. Cell Death & Disease
- Vasculogenic mimicry formation in EBV-associated epithelial malignancies
- (2018) Tong Xiang et al. Nature Communications
- Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
- (2017) Khurum Khan et al. GUT
- Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
- (2017) Keehoon Jung et al. JOURNAL OF CLINICAL INVESTIGATION
- Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents
- (2017) Minfeng Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses
- (2017) Timothy Cloughesy et al. JOURNAL OF CLINICAL ONCOLOGY
- The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
- (2017) Giovanni Luca Gravina et al. Journal of Hematology & Oncology
- Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation
- (2017) Mark Kin Fai Ma et al. JOURNAL OF HEPATOLOGY
- Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin
- (2017) Daniel Delgado-Bellido et al. Molecular Cancer
- Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
- (2017) Tabea Wiedmer et al. MOLECULAR CANCER THERAPEUTICS
- Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
- (2017) Peng Han et al. Molecular Oncology
- Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
- (2017) Rui-hua Xu et al. NATURE MATERIALS
- Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
- (2017) B A Castro et al. ONCOGENE
- Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer
- (2017) Arman Jahangiri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting CXCR4-dependent immunosuppressive Ly6Clowmonocytes improves antiangiogenic therapy in colorectal cancer
- (2017) Keehoon Jung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
- (2017) M. Wroblewski et al. Nature Communications
- DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA
- (2017) Huayue Lin et al. EBioMedicine
- A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
- (2016) W. M. Tai et al. ANNALS OF ONCOLOGY
- Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas
- (2016) Saori Okamoto et al. Brain Tumor Pathology
- MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
- (2016) C Marcela Diaz-Montero et al. BRITISH JOURNAL OF CANCER
- Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
- (2016) Le Qu et al. CANCER CELL
- Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
- (2016) Hsiao-Hui Lin et al. CANCER LETTERS
- Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade
- (2016) Alexandra Eichten et al. CANCER RESEARCH
- Endothelial Side Population Cells Contribute to Tumor Angiogenesis and Antiangiogenic Drug Resistance
- (2016) H. Naito et al. CANCER RESEARCH
- Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy
- (2016) S. Matsusaka et al. CLINICAL CANCER RESEARCH
- Role of the tumor stroma in resistance to anti-angiogenic therapy
- (2016) Elisabeth J.M. Huijbers et al. DRUG RESISTANCE UPDATES
- Lysosomes as mediators of drug resistance in cancer
- (2016) Benny Zhitomirsky et al. DRUG RESISTANCE UPDATES
- Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
- (2016) Shao-Lai Zhou et al. GASTROENTEROLOGY
- Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination
- (2016) Amalia Azzariti et al. HEPATOLOGY
- Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis
- (2016) Xiaofang Sun et al. HEPATOLOGY
- FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal
- (2016) Monika Haemmerle et al. JOURNAL OF CLINICAL INVESTIGATION
- Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
- (2016) Abin You et al. Journal of Hematology & Oncology
- ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α
- (2016) Fu-Quan Wu et al. JOURNAL OF HEPATOLOGY
- Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models
- (2016) Victoria L Bridgeman et al. JOURNAL OF PATHOLOGY
- Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
- (2016) Elizabeth A. Kuczynski et al. JNCI-Journal of the National Cancer Institute
- Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth
- (2016) Jie Huang et al. MOLECULAR CANCER THERAPEUTICS
- TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy
- (2016) Satoshi Matsusaka et al. MOLECULAR CANCER THERAPEUTICS
- Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
- (2016) S. Y. Park et al. MOLECULAR CANCER THERAPEUTICS
- Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
- (2016) Sophia Frentzas et al. NATURE MEDICINE
- Epithelial–mesenchymal transition: a new target in anticancer drug discovery
- (2016) Fabrizio Marcucci et al. NATURE REVIEWS DRUG DISCOVERY
- Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
- (2016) Yuji Piao et al. NEURO-ONCOLOGY
- Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma
- (2016) Z Xu et al. ONCOGENE
- Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
- (2016) N. N. Rahbari et al. Science Translational Medicine
- Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
- (2016) P-F Zhang et al. Cell Death & Disease
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
- (2016) Gabriela Jiménez-Valerio et al. Cell Reports
- Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics
- (2016) Paloma Navarro et al. Cell Reports
- Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
- (2016) Elizabeth Allen et al. Cell Reports
- Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
- (2016) Laura Pisarsky et al. Cell Reports
- Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
- (2016) Elizabeth A. Kuczynski et al. JNCI-Journal of the National Cancer Institute
- The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis
- (2016) W. Liang et al. Cancer Immunology Research
- PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression
- (2015) Tao Luo et al. Autophagy
- Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
- (2015) A J Weickhardt et al. BRITISH JOURNAL OF CANCER
- Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
- (2015) A. Scholz et al. EMBO Molecular Medicine
- Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
- (2015) Victoria Tovar et al. GUT
- Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
- (2015) Xiaofang Sun et al. HEPATOLOGY
- Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- (2015) V. L. Bridgeman et al. MOLECULAR CANCER THERAPEUTICS
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
- (2015) Atsushi Mitsuhashi et al. Nature Communications
- Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
- (2015) Lee B. Rivera et al. Cell Reports
- Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2
- (2015) Doruk Keskin et al. Cell Reports
- MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib
- (2015) Paola Stiuso et al. Molecular Therapy-Nucleic Acids
- Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
- (2015) Benny Zhitomirsky et al. Oncotarget
- Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
- (2014) Fred Fack et al. ACTA NEUROPATHOLOGICA
- Metabolic effects of antiangiogenic drugs in tumors: Therapeutic implications
- (2014) Luigi Quintieri et al. BIOCHEMICAL PHARMACOLOGY
- 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2
- (2014) Li Ma et al. CANCER LETTERS
- Monocyte Subpopulations in Angiogenesis
- (2014) H. J. Dalton et al. CANCER RESEARCH
- Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
- (2014) Diego O. Croci et al. CELL
- Blocking Lipid Synthesis Overcomes Tumor Regrowth and Metastasis after Antiangiogenic Therapy Withdrawal
- (2014) Nor Eddine Sounni et al. Cell Metabolism
- Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer
- (2014) Danfang Zhang et al. Molecular Cancer
- Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer
- (2014) B. S. Guerrouahen et al. MOLECULAR CANCER THERAPEUTICS
- Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
- (2014) E. Ciamporcero et al. MOLECULAR CANCER THERAPEUTICS
- Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts
- (2014) Kiersten Marie Miles et al. PLoS One
- Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest
- (2014) S Raz et al. Cell Death & Disease
- Vascular channels formed by subpopulations of PECAM1+ melanoma cells
- (2014) James M. Dunleavey et al. Nature Communications
- Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models
- (2013) Xiao-Dong Zhu et al. ANGIOGENESIS
- Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes
- (2013) J. Ruan et al. BLOOD
- Autotaxin-Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma
- (2013) S.-C. Su et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Neutrophils Promote the Malignant Glioma Phenotype through S100A4
- (2013) J. Liang et al. CLINICAL CANCER RESEARCH
- Cell Trafficking of Endothelial Progenitor Cells in Tumor Progression
- (2013) P. de la Puente et al. CLINICAL CANCER RESEARCH
- Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma
- (2013) Yingjian Liang et al. HEPATOLOGY
- Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy
- (2013) Leisa Johnson et al. JOURNAL OF CLINICAL INVESTIGATION
- Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
- (2013) Jonathan Welti et al. JOURNAL OF CLINICAL INVESTIGATION
- Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy
- (2013) Limin Huang et al. Journal of Hematology & Oncology
- IL-17 mediates resistance to anti-VEGF therapy
- (2013) Eleni Maniati et al. NATURE MEDICINE
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
- (2013) Alicia S Chung et al. NATURE MEDICINE
- The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
- (2013) Christopher H. Lieu et al. PLoS One
- Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment
- (2013) V. T. Phan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD44 Expressed on Cancer-Associated Fibroblasts Is a Functional Molecule Supporting the Stemness and Drug Resistance of Malignant Cancer Cells in the Tumor Microenvironment
- (2013) Yumi Kinugasa et al. STEM CELLS
- Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis
- (2013) Kayoko Hosaka et al. Nature Communications
- Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment
- (2012) Kosuke Akiyama et al. AMERICAN JOURNAL OF PATHOLOGY
- Contrasting effects of sunitinib within in vivo models of metastasis
- (2012) Jonathan C. Welti et al. ANGIOGENESIS
- Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy
- (2012) Yu-Long Hu et al. Autophagy
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
- (2012) Hannah van Malenstein et al. CANCER LETTERS
- Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
- (2012) Y.-L. Hu et al. CANCER RESEARCH
- Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients
- (2012) A. W. Griffioen et al. CLINICAL CANCER RESEARCH
- Sorafenib Down-regulates Expression of HTATIP2 to Promote Invasiveness and Metastasis of Orthotopic Hepatocellular Carcinoma Tumors in Mice
- (2012) Wei Zhang et al. GASTROENTEROLOGY
- Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
- (2012) Melissa Taylor et al. Cancer Discovery
- Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
- (2011) D. Y. Heng et al. ANNALS OF ONCOLOGY
- Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression
- (2011) M. Franco et al. BLOOD
- Periostin: a putative mediator involved in tumour resistance to anti-angiogenic therapy?
- (2011) Wei Wang et al. CELL BIOLOGY INTERNATIONAL
- Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
- (2011) A. M. Jubb et al. CLINICAL CANCER RESEARCH
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
- (2011) K. J. Gotink et al. CLINICAL CANCER RESEARCH
- Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways
- (2011) Nadine Rohwer et al. DRUG RESISTANCE UPDATES
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
- (2011) Tina Cascone et al. JOURNAL OF CLINICAL INVESTIGATION
- Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?
- (2011) Iris Helfrich et al. Molecular Oncology
- Pericytes and vessel maturation during tumor angiogenesis and metastasis
- (2010) Ahmad Raza et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
- (2010) Maya H. Nisancioglu et al. CANCER RESEARCH
- Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: Implications for future therapeutic approaches
- (2010) Stephen M. Schleicher et al. DRUG RESISTANCE UPDATES
- Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
- (2010) Iris Helfrich et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
- (2010) J C Welti et al. ONCOGENE
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
- (2009) Zvi G. Fridlender et al. CANCER CELL
- Cellular Source and Amount of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Tumors Determine Response to Angiogenesis Inhibitors
- (2009) B. Sennino et al. CANCER RESEARCH
- Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy
- (2009) A. K. Lucio-Eterovic et al. CLINICAL CANCER RESEARCH
- VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
- (2009) Marja Lohela et al. CURRENT OPINION IN CELL BIOLOGY
- Resistance to targeted therapy in renal-cell carcinoma
- (2009) Brian I Rini et al. LANCET ONCOLOGY
- G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
- (2009) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
- (2008) F. Shojaei et al. CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started